These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 26163610)

  • 1. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
    Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
    Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
    Sun N; Chen Z; Tan F; Zhang B; Yao R; Zhou C; Li J; Gao Y; Liu Z; Tan X; Zhou F; He MY; Shao K; Li N; Qiu B; Sun J; Yu Y; Wang S; Zhao Y; Shi X; He J
    Clin Cancer Res; 2013 Sep; 19(18):5136-45. PubMed ID: 24046070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
    Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
    Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
    Jiang ZF; Wang M; Xu JL
    Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Diagnostic and Prognostic Value of the Combination of Tumor M2-Pyruvate Kinase, Carcinoembryonic Antigen, and Cytokeratin 19 Fragment in Non-Small Cell Lung Cancer.
    Li L; Xu Y; Wang Y; Zhang Q; Wang Y; Xu C
    Technol Cancer Res Treat; 2024; 23():15330338241265983. PubMed ID: 39043046
    [No Abstract]   [Full Text] [Related]  

  • 8. Retrospective Study to Determine Diagnostic Utility of 6 Commonly Used Lung Cancer Biomarkers Among Han and Uygur Population in Xinjiang Uygur Autonomous Region of People's Republic of China.
    Yang-Chun F; Min F; Di Z; Yan-Chun H
    Medicine (Baltimore); 2016 May; 95(18):e3568. PubMed ID: 27149479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical Significance of Tumor Marker Detection in Patients 
with Advanced Squamous Cell Carcimoma of the Lung].
    Liang P; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):641-647. PubMed ID: 27760591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer.
    Wang L; Wang D; Zheng G; Yang Y; Du L; Dong Z; Zhang X; Wang C
    Int J Biol Markers; 2016 Feb; 31(1):e80-7. PubMed ID: 26560853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
    Hang ZQ; Zheng MF; Huang JH
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
    Front Immunol; 2020; 11():1173. PubMed ID: 32587591
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).
    Cedrés S; Nuñez I; Longo M; Martinez P; Checa E; Torrejón D; Felip E
    Clin Lung Cancer; 2011 May; 12(3):172-9. PubMed ID: 21663860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
    Ni J; Guo Z; Zhang L
    Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer.
    Chen ZQ; Huang LS; Zhu B
    Dis Markers; 2018; 2018():9845123. PubMed ID: 30647803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
    Jiang AG; Chen HL; Lu HY
    BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer.
    Bai Y; Shen W; Zhu M; Zhang L; Wei Y; Tang H; Zhao J
    J Cell Biochem; 2019 Jan; 120(1):105-114. PubMed ID: 30216488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Yamamoto N; Iida T
    Anticancer Res; 2003; 23(3C):2869-74. PubMed ID: 12926125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination.
    Wang WJ; Tao Z; Gu W; Sun LH
    Asian Pac J Cancer Prev; 2013; 14(7):4369-71. PubMed ID: 23992005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
    Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
    J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.